Service delivery models for injectable opioid agonist treatment in Canada: 2 sequential environmental scans
- PMID: 33622764
- PMCID: PMC8034381
- DOI: 10.9778/cmajo.20200021
Service delivery models for injectable opioid agonist treatment in Canada: 2 sequential environmental scans
Abstract
Background: Injectable opioid agonist treatment (iOAT) is an emerging evidence-based option in the continuum of care for opioid use disorder in parts of Canada. Our study objective was to identify and describe iOAT programs operating during the ongoing opioid overdose crisis.
Methods: We conducted 2 sequential environmental scans. Programs were eligible to participate if they were in operation as of Sept. 1, 2018, and Mar. 1, 2019. Information was collected over 2-3 months for each scan (September-October 2018, March-May 2019). Programs that participated in the first scan and newly established programs were invited to participate in the second scan. The scans included questions about location, service delivery model, clinical and operational characteristics, numbers and demographic characteristics of clients, and program barriers and facilitators. Descriptive analysis was performed.
Results: We identified 14 unique programs across the 2 scans. Eleven programs located in urban centres in British Columbia and Ontario participated in the first scan. At the time of the second scan, 2 of these programs were on hold and 2 of 3 newly established programs were in Alberta. The total capacity of all participating programs was 420 clients at most. Four service delivery models were identified; iOAT was most commonly integrated within existing health and social services. All programs offered hydromorphone, and 1 program also offered diacetylmorphine. In the first scan, 73% of clients (133/183) were male; the mean age of clients was 47 years. Limited capacity, pharmacy operations and lack of diacetylmorphine access were among the most frequently reported barriers. The most commonly reported facilitators included client-centred care, client relationships and access to other health and social support.
Interpretation: Evidence indicates that iOAT can be successfully implemented using diverse service delivery models. Future work should facilitate scale-up of this evidence-based treatment where gaps persist in high-risk communities.
© 2021 Joule Inc. or its licensors.
Conflict of interest statement
Competing interests: Christy Sutherland reports family investment in Adamis Pharmaceuticals during the conduct of the study. Marie-Ève Goyer reports receiving an honorarium and training support from Gilead Sciences, outside of the submitted work. Bernard Le Foll reports receiving grants from Pfizer, BrainsWay, Bioprojet, Alkermes, Canopy Growth and the American Chemical Society, as well as nonfinancial support from Aurora Cannabis, outside the submitted work. Christy Sutherland, Karine Meador, Michael Trew, Jeffrey Turnbull and Nadia Fairbairn were involved in the clinical provision of injectable opioid agonist treatment during the conduct of the study. No other competing interests were declared.
Figures
Similar articles
-
Barriers and facilitators to injectable opioid agonist treatment engagement within a structural vulnerability context: a qualitative study of patient experiences in Vancouver, Canada.Harm Reduct J. 2025 Jul 4;22(1):116. doi: 10.1186/s12954-025-01262-4. Harm Reduct J. 2025. PMID: 40615907 Free PMC article.
-
Client preferences for the design and delivery of injectable opioid agonist treatment services: Results from a best-worst scaling task.Addiction. 2024 Dec;119(12):2139-2150. doi: 10.1111/add.16620. Epub 2024 Jul 25. Addiction. 2024. PMID: 39054406
-
Injectable opioid agonist treatment: An evolutionary concept analysis.Res Nurs Health. 2021 Aug;44(4):664-671. doi: 10.1002/nur.22140. Epub 2021 May 16. Res Nurs Health. 2021. PMID: 33993526
-
Challenges for the implementation of injectable opioid agonist treatment: a scoping review.Harm Reduct J. 2024 Dec 4;21(1):217. doi: 10.1186/s12954-024-01102-x. Harm Reduct J. 2024. PMID: 39633369 Free PMC article.
-
Measuring the preferences of injectable opioid agonist treatment (iOAT) clients: Development of a person-centered scale (best-worst scaling).Int J Drug Policy. 2023 Feb;112:103948. doi: 10.1016/j.drugpo.2022.103948. Epub 2022 Dec 29. Int J Drug Policy. 2023. PMID: 36586152 Review.
Cited by
-
Motivations to initiate injectable hydromorphone and diacetylmorphine treatment: A qualitative study of patient experiences in Vancouver, Canada.Int J Drug Policy. 2020 Nov;85:102930. doi: 10.1016/j.drugpo.2020.102930. Epub 2020 Sep 16. Int J Drug Policy. 2020. PMID: 32949832 Free PMC article.
-
A Case report of a continuous ambulatory drug delivery (CADD) pump to deliver opioid agonist treatment in an acute care setting.Harm Reduct J. 2023 Sep 4;20(1):123. doi: 10.1186/s12954-023-00813-x. Harm Reduct J. 2023. PMID: 37661267 Free PMC article.
-
The changing landscape of pharmaceutical alternatives to the unregulated drug supply during COVID-19.Harm Reduct J. 2022 Jul 14;19(1):77. doi: 10.1186/s12954-022-00657-x. Harm Reduct J. 2022. PMID: 35836189 Free PMC article.
-
"I'm just searching to get better": Constructions of treatment citizenship on injectable opioid agonist treatment.Soc Sci Med. 2024 May;348:116708. doi: 10.1016/j.socscimed.2024.116708. Epub 2024 Mar 20. Soc Sci Med. 2024. PMID: 38531216 Free PMC article.
-
Women's experiences in injectable opioid agonist treatment programs in Vancouver, Canada.Int J Drug Policy. 2023 Jul;117:104054. doi: 10.1016/j.drugpo.2023.104054. Epub 2023 May 14. Int J Drug Policy. 2023. PMID: 37192557 Free PMC article.
References
-
- Special Advisory Committee on the Epidemic of Opioid Overdoses. Opioid-related harms in Canada. Ottawa: Public Health Agency of Canada; [accessed 2020 June 15]. modified 2020 Sept. 30. Available: https://health-infobase.canada.ca/substance-related-harms/opioids.
-
- Wood E. Strategies for reducing opioid-overdose deaths. N Engl J Med. 2018;378:1565–7. - PubMed
-
- National injectable opioid agonist treatment for opioid use disorder operational guidance. Canadian Research Initiative in Substance Misuse; 2019. [accessed 2019 Dec 7]. Available: https://crism.ca/wp-content/uploads/2019/09/CRISM_National_IOAT_Operatio....
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical